Drug Combination Details
| General Information of the Combination (ID: C29668) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Itraconazole Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Skin basal cell carcinoma
[ICD-11: 2C32]
|
Phase 1 | [1] | ||
|
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | ||
| Experimental
Result(s) |
ATO combined with ITRA can more strongly suppress the growth of multiple myeloma NCI-H929 cells, as compared with a single administration. The synergistic effect of ATO and ITRA significantly down-regulates expression of Gli1 in HH signaling pathway, moreover the inhibition of target gene overexpression may be one of two drug mechanisms. | |||||
